Good news for company and also all patients - the efficacy could be much higher than egg based vaccines available
“5. Conclusions
Recent experience with the rapid evolution of A(H3N2) influenza strains, and the consequent disappointing vaccine efficacy over multiple seasons, highlights the need for vaccine strategies which can provide protection against strains that have evolved beyond those included in the vaccine. A key aspect of future influenza vaccine antigen development, therefore, will be both the retention of the highly efficacious, but also highly strain-specific, immune responses evoked by current vaccines; complemented by induction of responses to highly conserved neutralizing epitopes which may be found not only in the stem, but also the head, of hemagglutinin [9].
Here we demonstrate that influenza HA nanoparticles, delivered with saponin-based Matrix-M™ adjuvant, are capable of eliciting both classical hemagglutination-inhibiting antibodies but also antibodies reactive with multiple broadly cross-reactive epitopes on hemagglutinin.”
News 
Market Data 
Discover 
AI
